Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Individualized GH treatme… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Individualized GH treatment reduces the variation in insulin levels and in body composition during the maintenance growth phase in prepubertal children

Paper i proceeding
Författare Ralph Decker
Kerstin Albertsson-Wikland
Berit Kriström
Maria Halldin
Jovanna Dahlgren
Publicerad i Horm Res Paediatr
Volym 2011
Nummer/häfte 76 (suppl)
Sidor 84
ISBN 978-3-8055-9835-4
Publiceringsår 2011
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för pediatrik
Sidor 84
Språk en
Ämnesord Maintenance growth period, growth hormone, individualized treatment, responsiveness, reduced dose
Ämneskategorier Klinisk farmakologi, Fysiologi

Sammanfattning

Background: Few studies have evaluated the metabolic outcomes of growth hormone (GH) treatment in prepubertal short children during different growth phases. We have studied individualized GH treatment in the catch-up growth phase and found a reduction in variation of fasting insulin levels by 34% compared to unchanged standard dose. Thereafter, GH-treated children appear to need lower GH doses to maintain SDscore channel-parallel growth. The individualized approach using prediction models for estimation of GH responsiveness has the advantage of narrowing the range of growth response around mid-parental heights, avoiding too low or high GH doses. Methods: Short prepubertal children with either isolated GHD or ISS participated in a 2-year randomized trial of either individualized GH treatment (range, 17–100 μg/kg/day) or a unchanged (USD) standard dose. After achieving near mid-parental height, children with individualized dosage were randomized to either reduced individualized dose (RID, n=28) (i.e. 50% decreased dose) or unchanged individualized dose (UID, n=37) for 2 more years. The 33 children randomized to the USD (43 μg/kg/day) at start of treatment remained unchanged. Objective and hypotheses: To evaluate if bisection of the reduced individualized GH dose (RID) diminishes the variation in the metabolic parameters measured during maintenance growth compared to reduced individualized GH dose. Hypothesis: Reduction of GH dosage reduces the range of metabolic outcomes without decreasing growth velocity during the maintenance growth phase. Results: : We observed a narrower variation in fasting insulin levels (-50%) and in insulin sensitivity as assessed by homoeostasis model assessment, HOMA (-55.1%), lean soft tissue, LST (-27.8%) and bone mineral content, BMC (-31.3%), in RID compared to UID (p<0.05).

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?